Published in Cancer Weekly, October 21st, 2003
The phase II clinical study assessed a two-part treatment consisting of CHOP chemotherapy (a combination-chemotherapy regimen) followed by the Bexxar therapeutic regimen. This is the first fully published study of a combination treatment involving chemotherapy and radioimmunotherapy in the first-line treatment of follicular NHL. The treatment produced an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.